Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Recent Advance in Thoracic Cancers Progressing after Chemo-/Immunotherapy
share announcement

Recent Advance in Thoracic Cancers Progressing after Chemo-/Immunotherapy

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 3175

Special Issue Editors

Dr. Daniel C. Christoph

E-Mail Website
Guest Editor
Department of Medical Oncology, Evang. Kliniken Essen-Mitte, 45136 Essen, Germany
Interests: lung cancer; malignant pleural mesothelioma; checkpoint inhibition; angiogenesis inhibition
Dr. Martin Faehling

E-Mail Website
Guest Editor
Department of Cardiology and Pneumology, Klinikum Esslingen, 73730 Esslingen, Germany
Interests: lung cancer; checkpoint inhibition; chemo-/radiotherapy; consolidating checkpoint inhibition; targeted therapy

Special Issue Information

Dear Colleagues,

Over the last few years, combined and simultaneously administered chemo-/immunotherapy as first-line systemic treatment has become the standard of care for the vast majority of patients suffering from locally advanced or metastatic non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC) and malignant pleural mesothelioma (MPM). However, regarding the optimum second-line or third-line (in case of consecutive administration) treatment after failure of this combined chemo-/immunotherapy, scientific discussions are ongoing, and particularly for NSCLC patients, the results of several phase 3 clinical trials (e.g. CONTACT-01, LEAP-008 or SAPPHIRE) are eagerly awaited. This Special Issue will focus on mechanisms causing resistance to chemo-/immunotherapy and options to overcome this resistance. Furthermore, means to avoid the development of resistance will be discussed.

Dr. Daniel C. Christoph
Dr. Martin Faehling
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • malignant pleural mesothelioma
  • chemotherapy
  • checkpoint inhibition
  • resistance
  • angiogenesis inhibition

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 953 KiB  
Article
A Comparison of Total Thoracoscopic and Robotic Surgery for Lung Cancer Lymphadenectomy
by Anna Ureña, Camilo Moreno, Ivan Macia, Francisco Rivas, Carlos Déniz, Anna Muñoz, Ines Serratosa, Marta García, Cristina Masuet-Aumatell, Ignacio Escobar and Ricard Ramos
Cancers 2023, 15(13), 3442; https://doi.org/10.3390/cancers15133442 - 30 Jun 2023
Cited by 4 | Viewed by 1088
Abstract
Background: Robotic-assisted thoracic surgery (RATS) is used increasingly frequently in major lung resection for early stage non-small-cell lung cancer (NSCLC) but has not yet been fully evaluated. The aim of this study was to compare the surgical outcomes of lymph node dissection (LND) [...] Read more.
Background: Robotic-assisted thoracic surgery (RATS) is used increasingly frequently in major lung resection for early stage non-small-cell lung cancer (NSCLC) but has not yet been fully evaluated. The aim of this study was to compare the surgical outcomes of lymph node dissection (LND) performed via RATS with those from totally thoracoscopic (TT) four-port videothoracoscopy. Methods: Clinical and pathological data were collected retrospectively from patients with clinical stage N0 NSCLC who underwent pulmonary resection in the form of lobectomy or segmental resection between June 2010 and November 2022. The assessment criteria were number of mediastinal lymph nodes and number of mediastinal stations dissected via the RATS approach compared with the four-port TT approach. Results: A total of 246 pulmonary resections with LND for clinical stages I–II NSCLC were performed: 85 via TT and 161 via RATS. The clinical characteristics of the patients were similar in both groups. The number of mediastinal nodes dissected and mediastinal stations dissected was significantly higher in the RATS group (TT: mean ± SD, 10.72 ± 3.7; RATS, 14.74 ± 6.3 [p < 0.001]), except in the inferior mediastinal stations. There was no difference in terms of postoperative complications. Conclusions: In patients with early stage NSCLC undergoing major lung resection, the quality of hilomediastinal LND performed using RATS was superior to that performed using TT. Full article
(This article belongs to the Special Issue Recent Advance in Thoracic Cancers Progressing after Chemo-/Immunotherapy)
►▼ Show Figures

Figure 1

13 pages, 2438 KiB  
Article
Stereotactic Body Radiotherapy versus Surgery for Lung Metastases from Colorectal Cancer: Single-Institution Results
by Nagore Garcia-Exposito, Ricard Ramos, Valentin Navarro-Perez, Kevin Molina, Maria Dolores Arnaiz, Susana Padrones, Jose Carlos Ruffinelli, Cristina Santos, Ferran Guedea and Arturo Navarro-Martin
Cancers 2023, 15(4), 1195; https://doi.org/10.3390/cancers15041195 - 13 Feb 2023
Cited by 1 | Viewed by 1806
Abstract
Background: Surgery and stereotactic body radiotherapy (SBRT) are two of the options available as local treatments for pulmonary oligometastases from colorectal cancer (CRC). We hypothesized that SBRT would have, at least, a similar local control rate to surgery. Methods: We identified an initial [...] Read more.
Background: Surgery and stereotactic body radiotherapy (SBRT) are two of the options available as local treatments for pulmonary oligometastases from colorectal cancer (CRC). We hypothesized that SBRT would have, at least, a similar local control rate to surgery. Methods: We identified an initial cohort of 100 patients with CRC who received SBRT or surgery for lung metastases. This was then narrowed down to 75 patients: those who underwent surgery (n = 50) or SBRT (n = 25) as their first local thoracic treatment between 1 January 2004 and 29 December 2017. The Kaplan–Meier method was used to calculate lung-progression-free survival (L-PFS) and overall survival (OS). Results: The 1 and 2-year L-PFS was 85% and 70% in the surgical group and 87% and 71% in the SBRT group, respectively (p = 0.809). No significant differences were found between the two groups in terms of OS. The biologically effective dose (BED), age and initial CRC stage did not have a significant effect on local control or survival. No grade 3 or above acute- or late-toxicity events were reported. Conclusions: These results add retrospective evidence that SBRT and surgery have similar results in terms of OS and local control in patients with lung oligometastases from CRC. Full article
(This article belongs to the Special Issue Recent Advance in Thoracic Cancers Progressing after Chemo-/Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop